Quince Therapeutics, Inc. (QNCX): Nasdaq/NYSE listing notice — Quince Therapeutics receives Nasdaq bid price deficiency notice; has until June 3, 2024 to regain compliance

Quince Therapeutics, Inc.

Received Nasdaq notice on Dec 4, 2023 for failing minimum bid price of $1.00 for 30 consecutive trading days.
Has 180 calendar days, until June 3, 2024, to regain compliance by closing bid >=$1.00 for 10 consecutive days.
If not compliant by June 3, may transfer to Nasdaq Capital Market for an additional 180-day compliance period.
No immediate effect on listing; company intends to monitor and consider options to cure deficiency.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Quince Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1), 5810(c)(3)(A)

Exact text from the filing

December 4, 2023, Quince Therapeutics, Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that, based on the closing bid price of the Company’s common stock, par value $0.001 per share (the “Common Stock”), for the last 30 consecutive trading days, the Company no longer complies with the minimum bid price requirement for continued listing on The Nasdaq Global Select Market. Nasdaq Listing Rule 5450(a)(1) requires listed securities to maintain a minimum bid price of $1.00 per share (t

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Quince Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-291671

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.